OR WAIT 15 SECS
The acquisition is expected to accelerate progress towards personalized cancer healthcare.
Roche has completed its previously announced $1.9-billion acquisition of Flatiron Health, a privately held healthcare technology and services company headquartered in New York, NY, the pharma major announced on April 6, 2018.
Under the agreement, Flatiron Health will continue to operate as a separate legal entity, and its current business model, network of partnerships, and overall objectives remain. The integrity of segregated patient-protected health information will be preserved, as will sales, marketing, provider-facing, and life science business activities.
Flatiron Health is a market leader in oncology-specific electronic health record (EHR) software as well as in the curation and development of real-world evidence for cancer research, Roche reports. Flatiron Health has created a technology platform designed to learn from the experience of every patient using a large network of community oncology practices and academic medical centers across the United States. The acquisition allows both companies to accelerate progress towards data-driven personalized healthcare in cancer.
Currently, Flatiron partners with more than 265 community cancer clinics, six major academic research centers, and 14 out of the top 15 therapeutic oncology companies.